Ramesh K Ramanathan

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi request reprint Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer
    Shelley Dranko
    University of Pittsburgh Cancer Institute, PA, USA
    Clin Colorectal Cancer 6:224-5. 2006
  2. ncbi request reprint Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies
    Ramesh K Ramanathan
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer Chemother Pharmacol 55:354-60. 2005
  3. ncbi request reprint Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 57:465-74. 2006
  4. ncbi request reprint A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 61:453-8. 2008
  5. ncbi request reprint Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Clin Cancer Res 13:1769-74. 2007
  6. pmc Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741
    Hanna K Sanoff
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 26:5721-7. 2008
  7. doi request reprint A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies
    Suresh S Ramalingam
    Authors Affiliations Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Clin Cancer Res 14:3456-61. 2008
  8. ncbi request reprint Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors
    Julie L Eiseman
    Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213 1863, USA
    Clin Cancer Res 13:2121-7. 2007
  9. ncbi request reprint Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers
    Ramesh K Ramanathan
    Molecular Therapeutics Drug Discovery Program, Biostatistics Department, Graduate School of Public Health, and Biostatistics Facility, University of Pittsburgh Cancer Institute, PA 15232, USA
    Clin Cancer Res 11:3385-91. 2005
  10. ncbi request reprint Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors
    William C Zamboni
    Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Clin Cancer Res 10:5058-64. 2004

Detail Information

Publications62

  1. ncbi request reprint Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer
    Shelley Dranko
    University of Pittsburgh Cancer Institute, PA, USA
    Clin Colorectal Cancer 6:224-5. 2006
    ..Ocular toxicity is uncommon. We report 2 cases of ocular toxicity characterized by blepharitis and conjunctivitis related to cetuximab administration. Strategies for management are discussed...
  2. ncbi request reprint Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies
    Ramesh K Ramanathan
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Cancer Chemother Pharmacol 55:354-60. 2005
    ..To improve the therapeutic index, we evaluated a weekly regimen of docetaxel in combination with capecitabine, and determined the maximum tolerated dose, toxicities and pharmacokinetics of this combination...
  3. ncbi request reprint Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 57:465-74. 2006
    ..The pharmacokinetics of MGd were also evaluated...
  4. ncbi request reprint A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 61:453-8. 2008
    ..Based on preclinical data that milataxel may be active in colorectal cancer (CRC), a phase II study was performed in patients with advanced previously treated CRC...
  5. ncbi request reprint Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Clin Cancer Res 13:1769-74. 2007
    ..The primary objective was to establish the dose-limiting toxicity (DLT) and recommended phase II dose of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) given twice a week...
  6. pmc Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741
    Hanna K Sanoff
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 26:5721-7. 2008
    ....
  7. doi request reprint A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies
    Suresh S Ramalingam
    Authors Affiliations Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Clin Cancer Res 14:3456-61. 2008
    ..We conducted a phase I study in patients with advanced malignancies to determine the recommended phase II dose of the combination of 17-AAG and paclitaxel...
  8. ncbi request reprint Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors
    Julie L Eiseman
    Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213 1863, USA
    Clin Cancer Res 13:2121-7. 2007
    ..Pretreatment plasma samples were also obtained from 12 healthy volunteers. Plasma IGFBP-2 and Her-2 ECD concentrations were quantitated by ELISA...
  9. ncbi request reprint Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers
    Ramesh K Ramanathan
    Molecular Therapeutics Drug Discovery Program, Biostatistics Department, Graduate School of Public Health, and Biostatistics Facility, University of Pittsburgh Cancer Institute, PA 15232, USA
    Clin Cancer Res 11:3385-91. 2005
    ..We did a phase I study of 17AAG to establish the dose-limiting toxicity and maximum tolerated dose and to characterize 17AAG pharmacokinetics and pharmacodynamics...
  10. ncbi request reprint Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors
    William C Zamboni
    Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Clin Cancer Res 10:5058-64. 2004
    ..In an effort to increase the dose administered per day and determine whether the daily dose or number of days of treatment influence toxicity, we performed a Phase I study of 9NC using intermittent schedules of administration...
  11. ncbi request reprint Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors
    Laura L Jung
    Molecular Therapeutics and Drug Discovery Program, University of Pittsburgh Cancer Institute, PA 15213, Pittsburgh, USA
    Cancer Chemother Pharmacol 54:487-96. 2004
    ..Therefore, we evaluated the plasma pharmacokinetics and urine recovery of 9NC administered on three different schedules as part of phase I and phase II studies...
  12. ncbi request reprint Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 13:3605-10. 2007
    ..The primary objective of this study was to determine the recommended phase II doses of the novel histone deacetylase inhibitor vorinostat when administered in combination with carboplatin and paclitaxel...
  13. ncbi request reprint Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma
    George van Buren
    Division of Surgical Oncology, UPMC Pancreatic Cancer Center, Pittsburgh, PA, USA
    Ann Surg Oncol 20:3787-93. 2013
    ....
  14. pmc Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors
    Ramesh K Ramanathan
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Clin Oncol 28:1520-6. 2010
    ..To define the maximum tolerated dose, toxicities, pharmacokinetics, and pharmacodynamics of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG)...
  15. ncbi request reprint A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer
    Khalid Matin
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Am J Clin Oncol 28:439-44. 2005
    ..Because the optimum dose of this combination was unknown, we used a phase I/II design...
  16. pmc Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors
    Abdulateef O Aregbe
    Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, 1001 W 10th Street, WD W7123, Indianapolis, IN 46202, USA
    Cancer Chemother Pharmacol 70:201-5. 2012
    ..To identify sources of exposure variability for the tumor growth inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) using a population pharmacokinetic analysis...
  17. doi request reprint Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer
    Benedito A Carneiro
    University of Pittsburgh Cancer Institute, PA 15232, USA
    Clin Colorectal Cancer 11:53-9. 2012
    ..Irinotecan and weekly cetuximab (I+C) is a standard second-line regimen for metastatic colorectal cancer (mCRC). This study investigated the safety and efficacy of every 2 weeks I+C in patients with mCRC...
  18. ncbi request reprint Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes
    William C Zamboni
    Hillman Cancer Research Center, Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Invest New Drugs 24:393-401. 2006
    ..The aim of this study was to evaluate the functional consequence of known single nucleotide polymorphisms in the transporter genes ABCB1, ABCC2, and ABCG2 on the pharmacokinetic disposition of 9NC and 9AC...
  19. ncbi request reprint The continuum of care: a paradigm for the management of metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Oncologist 12:38-50. 2007
    ....
  20. ncbi request reprint Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy
    Hitendra Patel
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA 15213, USA
    Invest New Drugs 24:359-63. 2006
    ..We evaluated oral rubitecan (5 days on, 2 days rest per week) on a continuous schedule, in patients with advanced colorectal cancer (CRC), who progressed after 5-fluorouracil based chemotherapy...
  21. doi request reprint A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer
    Rajesh Sehgal
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Clin Colorectal Cancer 10:117-20. 2011
    ..A week on/week off capecitabine schedule with oxaliplatin/bevacizumab was evaluated in patients with metastatic colorectal cancer (mCRC)...
  22. ncbi request reprint Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    Cancer Invest 22:858-65. 2004
    ....
  23. ncbi request reprint Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans
    Sakkaraiappan Ramalingam
    Divison of Hemotology Oncology, Deparatment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Pharmacotherapy 24:1232-5. 2004
    ..8% of the daily dose and CGP 74588 accounted for 0.2%. These data show both the qualitative similarities and the quantitative variability in biliary excretion of imatinib and its principal metabolite...
  24. ncbi request reprint A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Cancer Chemother Pharmacol 64:777-83. 2009
    ..To evaluate the response to lapatinib, an inhibitor of epidermal growth factor receptors 1 and 2, in patients with advanced bilary tree cancer (BTC) and hepatocellular cancer (HCC)...
  25. ncbi request reprint A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Building, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 22:23-30. 2004
    ..In this study, we compared the activity and toxicity of three different two-drug combinations in patients with metastatic colorectal cancer who had not been treated previously for advanced disease...
  26. ncbi request reprint A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 13:2109-14. 2007
    ..Objectives of this study were to determine safety, tolerability, pharmacodynamics, and pharmacokinetics of PX-12, a small-molecule inhibitor of Trx-1...
  27. ncbi request reprint Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma
    Mace L Rothenberg
    Division of Hematology Oncology, Vanderbilt Ingram Cancer Center, Nashville, TN 37232 6307, USA
    J Clin Oncol 23:9265-74. 2005
    ..Serial serum samples were measured for amphiregulin and transforming growth factor-alpha (TGFalpha)...
  28. ncbi request reprint Update for surgeons: recent and noteworthy changes in therapeutic regimens for cancer of the colon and rectum
    Claudia Hriesik
    Department of Surgery, Division of Surgical Oncology, University of Pittsburgh School of Medicine, and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15261, USA
    J Am Coll Surg 205:468-78 (Quiz 524). 2007
  29. ncbi request reprint A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, PA, USA
    Clin Colorectal Cancer 7:134-9. 2008
    ..This randomized, multicenter phase II trial was designed to evaluate and compare the efficacy of 4 different oxaliplatin/5-FU regimens...
  30. ncbi request reprint Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case
    Shelly S Lo
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15232, USA
    Dis Colon Rectum 48:1316-9. 2005
    ..Current studies are underway that may help us optimize the treatment for patients with gastrointestinal stromal tumors...
  31. ncbi request reprint Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07
    J Philip Kuebler
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA, USA
    J Clin Oncol 25:2198-204. 2007
    ..This phase III clinical trial evaluated the impact on disease-free survival (DFS) of adding oxaliplatin to bolus weekly fluorouracil (FU) combined with leucovorin as surgical adjuvant therapy for stage II and III colon cancer...
  32. ncbi request reprint 17-dimethylaminoethylamino-17-demethoxygeldanamycin in patients with advanced-stage solid tumors and lymphoma: a phase I study
    Firas N Shadad
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center, PA 15232, USA
    Clin Lymphoma Myeloma 6:500-1. 2006
  33. ncbi request reprint Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma
    Robert A Parise
    Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, 15213, Pittsburgh, PA, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 783:231-6. 2003
    ..The LC-MS assay, which proved superior because of its greater sensitivity and relatively short (7 min) run time, should be an important tool for future pharmacokinetic analyses of docetaxel and paclitaxel...
  34. ncbi request reprint Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts
    William C Zamboni
    Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pennsylvania 15213 1863, USA
    Clin Cancer Res 11:4867-74. 2005
    ..These results suggest that the intermittent schedule of 9-nitrocamptothecin may be an active regimen in patients with colorectal carcinoma...
  35. ncbi request reprint Treatment of colon and rectal cancer
    David Blumberg
    Division of GI Surgical Oncology, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15261, USA
    J Clin Gastroenterol 34:15-26. 2002
    ..This review details many of these advances in a comprehensive manner and illustrates the necessity of a multidisciplinary approach for optimizing outcome for patients with these cancers...
  36. doi request reprint HER2 gene amplification and chromosome 17 copy number do not predict survival of patients with resected pancreatic adenocarcinoma
    Saima Sharif
    Allegheny Cancer Center, Pittsburgh, PA, USA
    Dig Dis Sci 53:3026-32. 2008
    ..Although a significant percentage (25%) of pancreatic cancers demonstrate amplification of the HER2 gene, we find no association of HER2 gene amplification or chromosome 17 hyperploidy with poorer survival...
  37. ncbi request reprint A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma
    Cathy Eng
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    Am J Clin Oncol 27:565-9. 2004
    ..Grade 3/4 nonhematologic toxicities were minimal. We conclude that fixed dose rate gemcitabine results in significant myelosuppression and has minimal activity in patients with biliary tree carcinoma...
  38. ncbi request reprint Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    J Clin Oncol 21:2904-11. 2003
    ....
  39. ncbi request reprint Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Clin Oncol 20:4313-8. 2002
    ..To determine whether granulocyte-macrophage colony-stimulating factor (GM-CSF) would improve response to influenza vaccination in cancer patients...
  40. ncbi request reprint Multimodality treatment in a case of primary cardiac lymphoma
    Shelly S Lo
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Clin Lymphoma 4:112-4. 2003
    ..The patient in this report underwent successful surgical resection of a PCL. We now describe her multimodality treatment including autologous stem cell transplantation which resulted in a 22 month survival...
  41. ncbi request reprint Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer
    Ramesh K Ramanathan
    UPMC Cancer Pavilion, University of Pittsburgh Cancer Institute, 5150 Centre Avenue, 562, Pittsburgh, PA 15232, USA
    Cancer Immunol Immunother 54:254-64. 2005
    ..Further evaluation is warranted to examine the effect on disease-free survival and overall survival, especially in early disease and in the absence of immunosuppressive standard therapy...
  42. ncbi request reprint Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma
    Robert A Parise
    Program of Molecular Therapeutics and Drug Discovery, University of Pittsburgh Cancer Institute, Biomedical Science Tower, E 1040, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 791:39-44. 2003
    ..We believe that this LC-MS assay should be an important tool for future pharmacokinetic studies of imatinib...
  43. ncbi request reprint Mucins in gastrointestinal cancers
    Michael S Turner
    Department of Immunology, University of Pittsburgh School of Medicine, Cancer Center, PA 15261, USA
    Cancer Chemother Biol Response Modif 21:259-74. 2003
    ..This chapter aimed to highlight some of these opportunities and to interest clinician scientists in exploring them in the near future...
  44. ncbi request reprint Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group
    James H Doroshow
    Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Semin Oncol 30:14-9. 2003
    ....
  45. doi request reprint Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study
    Howard S Hochster
    New York University Cancer Institute, 160 East 34th St, New York, NY 10016, USA
    J Clin Oncol 26:3523-9. 2008
    ..To evaluate the safety and efficacy of three oxaliplatin and fluoropyrimidine regimens, with or without bevacizumab, as first-line treatment for metastatic colorectal cancer (CRC)...
  46. doi request reprint Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107
    Axel Grothey
    Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 26:183-9. 2008
    ..As these two superior therapies have differing mechanisms of action, we explored whether the improved survival associated with the superior therapy was dependent on tumor response...
  47. ncbi request reprint Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma
    Manish A Shah
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 24:5201-6. 2006
    ..We evaluated the efficacy and safety of the addition of bevacizumab to chemotherapy in the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma...
  48. ncbi request reprint Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group
    Chris H Takimoto
    Medicine Branch at Navy, National Naval Medical Center, National Cancer Institute, Bethesda, MD, USA
    Semin Oncol 30:20-5. 2003
    ..These data suggest that dose reductions of single-agent oxaliplatin are not necessary in patients with CrCLs >20 mL/min...
  49. ncbi request reprint Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
    Chris H Takimoto
    University of Texas Health Science Center at San Antonio, Cancer Therapy and Research Center, 7979 Wurzbach Rd, Room Z415, San Antonio, TX 78229, USA
    J Clin Oncol 21:2664-72. 2003
    ..This study was undertaken to determine the toxicities, pharmacokinetics, and maximum tolerated doses of oxaliplatin in patients with renal impairment and to develop formal guidelines for oxaliplatin dosing in this patient population...
  50. ncbi request reprint Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial
    Mace L Rothenberg
    Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232 6307, USA
    J Clin Oncol 21:2059-69. 2003
    ..In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus fluorouracil (FU), and leucovorin (IFL)...
  51. ncbi request reprint Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies
    Xueyu Chen
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Room 5 221A, 610 University Ave, Toronto, ON, Canada, M5G 2M9
    Cancer Chemother Pharmacol 55:237-43. 2005
    ....
  52. ncbi request reprint Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 14:1402-10. 2005
    ..The insulin-like growth factor (IGF) family of proteins is associated with QOL in noncancer populations. We sought to study whether these proteins are associated with QOL in patients with colorectal cancer...
  53. ncbi request reprint Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial
    Richard M Goldberg
    Division of Hematology and Oncology, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Bldg, Chapel Hill, NC 27514, USA
    J Clin Oncol 24:3347-53. 2006
    ..High rates of grade > or = 3 toxicity on IFL (resulting in some deaths) led us to reduce the starting doses of both irinotecan and FU by 20% (rIFL). This article compares rIFL with FOLFOX4...
  54. ncbi request reprint Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer
    Amanda C Ashley
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 110:670-7. 2007
    ..Efficacy and toxicity of oxaliplatin (Eloxatin; Sanofi-Aventis, Paris, France) combined with irinotecan (IROX) were examined in 383 patients enrolled on the IROX arm of Intergroup Study N9741...
  55. ncbi request reprint Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study
    Timothy W Synold
    City of Hope Comprehensive Cancer Center, Duarte, California, USA
    Clin Cancer Res 13:3660-6. 2007
    ..To determine the toxicities, pharmacokinetics, and maximally tolerated doses of oxaliplatin in patients with hepatic impairment and to develop formal guidelines for oxaliplatin dosing in this patient population...
  56. ncbi request reprint Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741
    Grace K Dy
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 25:3469-74. 2007
    ..To evaluate clinical characteristics and survival outcomes among patients with locally advanced or metastatic colorectal cancer who achieve a complete response (CR) to systemic treatment either alone or with multimodality approach...
  57. ncbi request reprint Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function
    Chris H Takimoto
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78245 3217, USA
    Clin Cancer Res 13:4832-9. 2007
    ..To characterize the pharmacokinetics and pharmacodynamics of oxaliplatin in cancer patients with impaired renal function...
  58. ncbi request reprint Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer
    Howard Hochster
    Cancer Institute, New York University Medical Center, 160 East 34th Street, 9th Floor, New York, NY 10016, USA
    Clin Colorectal Cancer 5:257-62. 2005
    ..The distinct mechanisms of action and patterns of resistance displayed by pemetrexed and irinotecan make them attractive agents for combination therapy...
  59. doi request reprint Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group
    Ramesh K Ramanathan
    Translational Genomics Research Institute, 13208 E Shea Blvd, Ste 100, Scottsdale, AZ 85259, USA
    J Clin Oncol 26:563-9. 2008
    ..To develop dosing guidelines and to evaluate the pharmacokinetics of imatinib in patients with liver dysfunction (LD)...
  60. doi request reprint Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group
    Joseph Gibbons
    Case Comprehensive Cancer Center, Ireland Cancer Center at University Hospitals of Case Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH, USA
    J Clin Oncol 26:570-6. 2008
    ....
  61. pmc The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma
    Amanda F Baker
    Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA
    J Lab Clin Med 147:83-90. 2006
    ..Furthermore, PX-12 decreases plasma VEGF levels that may contribute to the antitumor activity of PX-12...
  62. doi request reprint Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial
    Y Yen
    Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA 91010 3000, USA
    Am J Clin Oncol 31:317-22. 2008
    ..Oxaliplatin has recently demonstrated activity in HCC. The objective of this study was to determine the response rate, survival, time to progression, and toxicity in patients with poor prognosis HCC when treated with oxaliplatin...